Takeda Pharmaceutical Company Limited
TAK
Jodie situation report
Takeda Pharmaceutical Company Limited's current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 25 directly disclosed connections are confirming.
- TAK's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if TAK's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind TAK
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depended on by
EXEL7.7% of EXELcustomerMay 5, 2026 ▾
“During the three months ended March 31, 2026, we recognized $7.7 million in revenues in connection with an $8.0 million commercial milestone payment from Takeda, which was earned upon their achievement of $300.0 million of cumulative net sales of cabozantinib…”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 24 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
TAK is currently a Leader in the organic co-movement group Specialty Pharmaceuticals. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for TAK; it is not active in the latest market snapshot.